Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAITI: Holmium-166 TARE Followed by Maintenance Therapy in Liver-limited Unresectable Colorectal Cancer
2023-505356-22-00Phase 2Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Dec 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of holmium-166 in colorectal cancer (CRC) and colorectal adenocarcinoma (2 cohorts), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoints: Progression-free survival (PFS) rate at 9 months (Cohort A) and Progression-free survival (PFS) rate at 8 months (Cohort B). Started Dec 2023; status: completed.
02
Drugs
holmium-166
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2023-505356-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505356-22-00.